• Yuichiro Ogura, MD, PhD (Professor and Chair)
  • Munenori Yoshida, MD, PhD (Professor and vice chair)
  • Akiyoshi Uemura MD, PhD (Professor)
  • Tsutomu Yasukawa, MD, PhD (Associate Professor)
  • Miho Nozaki, MD, PhD (Associate Professor)
  • Hiroshi Morita, MD (Assistant Professor)
  • Aki Kato, MD, PhD (Associate Professor)
  • Yoshio Hirano, MD, PhD (Associate Professor)
  • Satoshi Ohta, MD(Assistant Professor)
  • Shinpei Fujino, MD (Assistant Professor)
  • Takeshi Mizutani, MD, PhD (Assistant Professor)
  • Masayo Kimura, MD (Assistant Professor)
  • Shuichiro Hirahara, MD (Assistant Professor)

Our Mission

To be a nationally recognized vision care center that serves the patients by providing exemplary patient care, founded on educational leadership, innovative research, community service, and high ethical standards.


Our focus is to unravel the mechanisms mediating ocular angiogenesis, such as age-related Macular Degeneration (AMD) and diabetic retinopathy. Using in vivo models, we have uncovered a critical role for leukocytes and adhesion molecules in the development abnormal blood vessels in the eye. We have also conducted several clinical studies that revealed the efficacy of new treatment for vitreo-retinal diseases.

  1. Leukocyte dynamics in retinal microcirculation
    We developed a new technique, which produces high-resolution images from a scanning laser ophthalmoscope using a fluorescent nuclear dye, acridine orange. This technique allows us to visualize, in vivo, leukocyte movements and leukocyte-endothelial interactions in the retinal microcirculation non-invasively. Applying this technique on rats, we have evaluated leukocyte behaviors in the retina in experimental models of diabetes, endotoxin-induced uveitis, interferon-associated retinopathy, chorioretinal ischemia and chromic hypercholesterolemia.
  2. Drug delivery systems (DDSs) for vitreo-retinal diseases
    Chorioretinal tissues are refractory to eye drops and systemic administration. To overcome this pharmaceutical problem, we aim to develop new DDSs involving: (1) controlled (sustained) release systems such as microspheres and scleral biodegradable implants, which are made of mixture of biodegradable polymers (e.g.; poly(lactic-co-glycolic acid)) and active pharmaceutical ingredients and (2) drug targeting, which is achieved by modifying molecular weight of drugs through the conjugation to water-soluble polymers. We believe that our contribution to the development of controlled drug delivery systems have lead to some recent clinical trials of biodegradable devices in the treatment of macular edema.
  3. Pathophysiology of diabetic retinopathy

    We studied the distribution of adhesion molecules, ICAM-I and P-Selectin in the retinal vessels of both spontaneously occurring and drug-induced diabetic rats.Based on the results, we clarified the role of adhesion molecules in the pathogenic mechanism of diabetic retinopathy.

  4. A novel three-dimensional culture system of retinal pigment epithelial (RPE) cells
    We established a novel 3D-culture system of RPE cells, which enhanced the formation of well differentiated epithelium accompanying Bruch’s membrane. This culture system may be useful to clarify unknown physiological functions of RPE especially on the basal side such as Bruch’s membranogenesis (elastogenesis) and lipoproteins secretion and to elucidate pathogenesis of RPE-related diseases involving AMD and retinitis pigmentosa.

Contact Information

Department of Ophthalmology and Visual Science,
Nagoya City University Graduate School of Medical Sciences
1 Kawasumi, Mizuho-cho, Mizuho-ku
JAPAN 467-8601
TEL: +81-52-853-8251
FAX: +81-52-841-9490